ACIP: Influenza Vaccination Recommendations for 2020-2021
Influenza vaccination should occur by the end of October, if possible.
Influenza vaccination should occur by the end of October, if possible.
HHS issued the amendment in order to increase access to childhood vaccines and decrease the risk of vaccine-preventable disease outbreaks as children return to daycare and school.
Influenza vaccinations were found to be underutilized among groups who are considered to be at high risk for complications from infection.
Review of the Advisory Committee Immunization Practices updates to the pediatric immunization schedule and significant revisions to the adult immunization schedule.
Moderna is charging $37 a dose for its experimental vaccine, which is far more than what other companies say they plan to charge for their vaccines.
Simulation experiments demonstrated that a vaccine efficacy of 80% is required to extinguish the ongoing COVID-19 pandemic without any other additional measures.
Pfizer and BioNTech have selected a coronavirus disease 2019 (COVID-19) vaccine candidate and have initiated their phase 2/3 safety and efficacy trial.
Influenza hospitalizations were decreased among people with diabetes when vaccines were received in multiple influenza seasons.
Interim results from the phase 1/2 COV001 trial evaluating the vaccine candidate ChAdOx1 nCoV-19 (AZD1222) showed that vaccination led to strong immune responses against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in all evaluated participants.
From 2008 to 2018, there was an increase in shingles vaccination among adults aged 60 years and older, with demographic, socioeconomic, and geographic variations in vaccination rates.